See the interview with Abliva’s CEO Ellen K. Donnelly, in English, below.
See Ellen K.Donnelly present Abliva at BioStock Investor Meeting here:
In December last year, Abliva initiated a potentially pivotal phase II study with KL1333. The candidate is being developed for the treatment of primary mitochondrial disease in adults, a group of rare diseases that lack effective treatment. CEO Ellen K. Donnelly visited BioStock’s studio to tell us more.
Notes
Sprint Bioscience inleder samarbete inom MASH
Zealand Pharma reports positive Phase Ib results
Curasight submits application for Phase I study with uTREAT
Hansa Biopharma carries out a directed share issue of SEK 232 million
Bavarian Nordic sells Priority Review Voucher for 160 MUSD
NEWSLETTER
NEWS
FDA introduces fast track for drugs of national importance
Positive outcome in phase I/IIa study for Oncoinvent
Alzinova is pursuing partnerships at BIO
Upcoming events!
Investing in Life Science
Join us in beautiful Stockholm as we focus on early-, growth- and late-stage investments in life science. From business angels...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
Bispecific and Chinese the new black in cancer
The venture capital cycle is complete – we are back where we started
